Zydus Lifesciences Limited

NSE ZYDUSLIFE.NS

Zydus Lifesciences Limited Interest Coverage Ratio for the year ending March 31, 2024: 98.74

Zydus Lifesciences Limited Interest Coverage Ratio is 98.74 for the year ending March 31, 2024, a 371.65% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.
  • Zydus Lifesciences Limited Interest Coverage Ratio for the year ending March 31, 2023 was 20.94, a -19.03% change year over year.
  • Zydus Lifesciences Limited Interest Coverage Ratio for the year ending March 31, 2022 was 25.86, a 61.80% change year over year.
  • Zydus Lifesciences Limited Interest Coverage Ratio for the year ending March 31, 2021 was 15.98, a 182.90% change year over year.
  • Zydus Lifesciences Limited Interest Coverage Ratio for the year ending March 31, 2020 was 5.65, a -58.26% change year over year.
Key data
Date Interest Coverage Ratio Debt to Equity Ratio Interest Expense To Sales Inventory Turnover Ratio
Market news
Loading...
NSE: ZYDUSLIFE.NS

Zydus Lifesciences Limited

CEO Mr. Punit Patel
IPO Date July 1, 2002
Location India
Headquarters Zydus Corporate Park
Employees 26,921
Sector Health Care
Industries
Description

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

Similar companies

INDUSTOWER.NS

Indus Towers Limited

USD 3.93

6.33%

SYNGENE.NS

Syngene International Limited

USD 9.56

0.73%

ALKEM.NS

Alkem Laboratories Limited

USD 60.83

0.86%

MOTHERSON.NS

Samvardhana Motherson International Limited

USD 1.68

4.32%

GLAND.NS

Gland Pharma Limited

USD 19.28

-1.41%

StockViz Staff

January 16, 2025

Any question? Send us an email